Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YQYiHua QiuSKSteven M. Kornblau

Discussion

Loading...

Member takes

Overview

Observational analysis shows low wilms tumor 1 protein predicts worse prognosis in acute myelogenous leukemia, suggesting therapy adjustments may be necessary.

Key Points

  • Low wilms tumor 1 protein levels correlate with worse patient outcomes in acute myelogenous leukemia, particularly affecting remission duration.
  • Differential expression analysis identified key proteins, with significant findings within apoptosis regulation pathways.
  • Patients showing low wilms tumor 1 expression exhibited increased chemoresistance compared to those with high levels.
  • The unique proteomic signature of low wilms tumor 1 expression points to potential therapeutic targets like the VEGF signaling pathway.

Cite This Study

Qiu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3b5https://doi.org/10.1182/blood-2025-5271
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.2025
  2. 2Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  3. 3High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  4. 4Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia2025
  5. 5Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single‐center validation study2025 · 1 citations